In assessing whether at least one of these regimens is apropos for the patient’s cancer, pathologists are often required to interpret a plethora of predictive and prognostic biomarkers, of which the most commonly used in clinical practice are HER2, PD-L1, MSI, and TMB through a combination of ancillary tests including IHC, ISH, PCR, and NGS. This evidence concerns the gene CD274 and cancer.